Improved survival in patients with CALR1 compared to CALR2 mutated primary myelofibrosis: a meta-analysis

Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis

(2016) Hampig Raphael Kourie et al.   Clinical Lymphoma Myeloma & Leukemia

CALR, JAK2, and MPL Mutation Profiles in Patients With Four Different Subtypes of Myeloproliferative Neoplasms

(2015) Seon Young Kim et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms

(2015) D Pietra et al.   LEUKEMIA

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis

(2015) P Guglielmelli et al.   Blood Cancer Journal

From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms

(2014) M. Cazzola et al.   BLOOD

Calreticulin mutations in Chinese with primary myelofibrosis

(2014) B. Li et al.   HAEMATOLOGICA

Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution

(2014) X Cabagnols et al.   LEUKEMIA

Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact

(2014) A Tefferi et al.   LEUKEMIA

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE